GlassScriptPhysician profile
Lee R Carter
NPI 1437365012
$11,653.18
in general payments reported to CMS, 2019-2025
51 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $1,879 · 2021: $1,960 · 2022: $1,510 · 2023: $1,688 · 2024: $1,823 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,348 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,347.68 |
| Education | $198.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,560.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,396.27 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,188.11 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Otsuka America Pharmaceutical, INC. | $855.17 | 2019-2025 | Rexulti |
| Lilly USA, LLC | $846.88 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $613.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $462.07 | 2019-2024 | |
| Astellas Pharma US INC | $419.10 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.84 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $332.95 | 2023-2025 | Ibsrela |
| Abbott Laboratories | $330.19 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.20 | 2019-2025 | Synjardy, Jardiance |
| Sunovion Pharmaceuticals INC. | $271.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $265.52 | 2019-2023 | |
| Allergan, INC. | $218.65 | 2019-2020 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.